Year None202220212020201920182017 Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates Aug 08, 2022 Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC Jul 27, 2022 Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies Jun 24, 2022 Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Jun 03, 2022 Turning Point Therapeutics to Participate in Upcoming Investor Conferences May 26, 2022 Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer May 16, 2022 Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates May 10, 2022 Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy May 10, 2022 Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines May 05, 2022 Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study Apr 28, 2022 Pagination Current page 1 Page 2 Next page next › Last page last »